REG - Cellbxhealth PLC - Expert Consensus on CTCs; Update on Funding
04/11/2025 07:00
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251104:nRSD0160Ga&default-theme=true
RNS Number : 0160G Cellbxhealth PLC 04 November 2025
4 November 2025
CELLBXHEALTH plc ("the Company")
Independent Expert Consensus Confirms Clinical Relevance of CTCs and
Identifies Parsortix Platform as Leading Next-Generation Technology
Update on Funding
· Expert consensus predicts integration of CTC testing into routine
clinical practice within 5 years
· CTCs provide distinct and impactful information that is not captured
by circulating tumour DNA (ctDNA)
· 40% of the expert panel identified the Parsortix® platform as the
most promising next generation technology for clinical applications
Guildford, UK and Plymouth Meeting PA, USA, - 4 November 2025 - CELLBXHEALTH
plc (AIM:CLBX OTCQX:ANPCY), a global leader in circulating tumour cell (CTC)
intelligence, welcomes the publication of a major international expert
consensus confirming the growing clinical relevance of CTC analysis in cancer
management. The study, titled "International expert consensus on the clinical
integration of circulating tumor cells in solid tumors", and published in the
high-impact factor journal the European Journal of Cancer, highlights the
Parsortix® platform as a leading future technology for clinical application.
The paper publishes the consensus of 32 global oncologists and research
leaders who agree that CTCs provide unique biological insights not captured by
circulating tumour DNA (ctDNA), and that CTCs are poised to transform cancer
care through their use in prognosis, treatment monitoring and characterisation
to inform precision medicine.
90% of respondents believe that CTCs will become a routine part of clinical
practice within the next five years and strongly support their use in
metastatic cancer. The publication provides a consensus for the clinical use
of CTCs across cancer types, removing the biggest historical barrier of
clinical scepticism, and is intended to guide the integration of CTCs into
oncologic practice.
The Company believes this publication strengthens the foundation for clinical
adoption of CTC-based technologies, aligning with its mission to advance
precision oncology.
Update on Funding
Further to the interim results of 9 October 2025, the Company currently has a
cash runway into early 2026. CelLBxHealth has recently commenced discussions
with a number of shareholders and is seeking to raise approximately £6m with
the intention to make an offer to retail investors alongside an institutional
placing.
The Company expects to announce the fundraise by early December and will make
further updates as appropriate.
Peter Collins, Chief Executive Officer of CelLBxHealth, said: "This
independent expert consensus further demonstrates the important role that CTCs
stand to play in cancer treatment into the future, and identifies the
Parsortix® platform as a go-to platform in the space. In this context,
CelLBxHealth is uniquely positioned as the next generation standard to enable
clinicians and researchers to harness the full diagnostic and therapeutic
potential of CTCs.
We look forward to engaging with shareholders and potential investors as we
reset the Company to deliver sustainable growth."
The peer reviewed manuscript, is available online: Nicolò, E. et al. (2025).
International expert consensus on the clinical integration of circulating
tumor cells in solid tumors. European Journal of Cancer, 231, 116050.
https://doi.org/10.1016/j.ejca.2025.116050
For more information, visit www.CelLBxHealth.com (http://www.CelLBxHealth.com)
For further information:
CelLBxHealth plc +44 (0) 1483 343434
Peter Collins, Chief Executive Officer investors@CelLBxHealth.com
Cavendish (NOMAD and Broker)
Geoff Nash / Isaac Hooper (Corporate Finance) +44 (0) 20 7220 0500
Sunila de Silva (Corporate Broking)
Nigel Birks (Life Science Specialist Sales)
FTI Consulting
Simon Conway, Ciara Martin, Sam Purewal +44 (0) 203 727 1000
Matthew Ventimiglia (US) +1 (212) 850 5624
The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the EU Market Abuse
Regulation (596/2014). Upon the publication of this announcement via a
regulatory information service, this information is considered to be in the
public domain.
Notes for editors
About CelLBxHealth plc
CelLBxHealth plc is a global precision CTC intelligence company specialising
in innovative circulating tumour cell (CTC) solutions for use in research,
drug development and clinical oncology. Its patent-protected Parsortix®
platform harvests CTCs from blood and can be seamlessly integrated with
existing laboratory instruments for comprehensive downstream analysis -
including whole-cell imaging, proteomic profiling and full genomic workflows.
Commercial activities centre on (1) Product Sales: Accelerating Parsortix
platform adoption and consumable sales through CROs* and clinical lab
partnerships. (2) Lab Developed Tests (LDTs): Strategic partnerships combined
with a focused in-house development programme (3) Laboratory services:
Clinical trial support and assay development.
The product portfolio comprises the Parsortix® platform with associated
consumables and assays. Laboratory services are delivered from CelLBxHealth's
GCLP certified UK laboratory, providing bespoke clinical-trial support and
assay development.
For more information, visit www.angleplc.com (http://www.angleplc.com) .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END UPDEAAFDEANSFAA
Copyright 2019 Regulatory News Service, all rights reserved